Back

Prognostic value of hyperkalemia and mineralocorticoid receptor antagonist use in heart failure: a national registry study

10 May 2026 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Mineralocorticoid receptor antagonists: from trials to real life Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Kristian Berge

Akershus University Hospital - AHUS, Nordbyhagen (Norway)

5 More presentations in this session

Presentation thumbnail
Temporal trends in mineralocorticoid receptor antagonist use among patients with heart failure in a community-based cohort
Doctor A. Ambrosy (San Francisco, US)
Abstract Slides Video
Presentation thumbnail
Finerenone: from evidence to clinical practice. Data from the finerlife registry (finerenone in real life)
Mr A. Hernandez Concepcion (Palmas de Gran Canaria, Las, ES)
Abstract Slides Video
Presentation thumbnail
SENEKA: a randomized clinical trial to optimize RAASi therapy using sodium zirconium cyclosilicate in elderly patients with heart failure and chronic kidney disease at risk of hyperkalemia
Doctor C. Bonanad Lozano (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Mineralocorticoid receptor antagonists in heart failure: real-world uptake, dose titration, hyperkalaemia trends, and potassium binder use
Doctor T. Furlan (Trbovlje, SI)
Abstract Slides Video
Presentation thumbnail
Real-life indications of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction
Doctor G. Antonelli (Rozzano, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Mineralocorticoid receptor antagonists: from trials to real life

The Event

Event poster

Heart Failure 2026

10 May 2026 10:30 CET
You may be interested in
thumbnail
Congress Presentation
Initiation of mineralocorticoid receptor antagonists in patients with cardiorenal diseases: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study
thumbnail
Congress Presentation
Unlocking survival: assessment of potassium levels in heart failure with quadruple guideline directed medical therapy across all ejection fraction spectrum
thumbnail
Congress Presentation
Hyperkalemia events in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan or sodium-glucose transport protein 2 inhibitors: a single-center experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources